Escin ameliorates the impairments of neurological function and blood brain barrier by inhibiting systemic inflammation in intracerebral hemorrhagic mice.
Animals
Blood-Brain Barrier
/ drug effects
Body Water
/ metabolism
Cardiovascular Agents
/ therapeutic use
Cerebral Hemorrhage
/ drug therapy
Escin
/ therapeutic use
Interleukin-1beta
/ blood
Male
Mice
Monocytes
/ drug effects
NF-kappa B
/ drug effects
Nervous System Diseases
/ drug therapy
Signal Transduction
/ drug effects
Systemic Inflammatory Response Syndrome
/ drug therapy
rhoA GTP-Binding Protein
/ drug effects
Blood brain barrier
Escin
Intracerebral hemorrhage
Systemic inflammation
Journal
Experimental neurology
ISSN: 1090-2430
Titre abrégé: Exp Neurol
Pays: United States
ID NLM: 0370712
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
24
08
2020
revised:
07
11
2020
accepted:
07
12
2020
pubmed:
15
12
2020
medline:
14
9
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
This study aims to investigate whether escin ameliorates the impairments of neurological function by ameliorating systemic inflammation instead of targeting the brain directly in intracerebral hemorrhage (ICH) mice. It showed that escin did not cross the blood brain barrier (BBB). Compared with the ICH group, the Garcia test scores in the escin groups were significantly increased. Brain water contents and Evans blue extravasation of the right basal ganglia in the ICH group were augmented, and significantly reduced by escin. Escin abated the increases of monocyte counts and serum IL-1β levels induced by ICH. IL-1β administration reversed the effect of escin on Garcia test scores, the brain water contents, and the Evans blue extravasation. Escin ameliorated the increasing levels of RhoA, ROCK1, nuclear NF-κB and the decreasing expression of IκBα, cytosolic NF-κB, occludin, claudin-5 in the ICH group. IL-1β administration blocked not only escin-mediated increases of IκBα, cytosolic NF-κB, occludin, and claudin-5, but also escin-caused decreases of RhoA, ROCK1, and nuclear NF-κB. The results indicate that escin improves neurological outcomes and the BBB function in ICH mice, which is associated with attenuating ICH-induced peripheral system inflammation, and therefore, inhibiting IL-1β/RhoA/NF-κB signaling pathway in BBB, at least in part. These findings suggest that it may be useful to ameliorate brain injury by inhibiting systemic inflammation instead of aiming to target the brain directly after ICH.
Identifiants
pubmed: 33309746
pii: S0014-4886(20)30385-X
doi: 10.1016/j.expneurol.2020.113554
pii:
doi:
Substances chimiques
Cardiovascular Agents
0
Interleukin-1beta
0
NF-kappa B
0
Escin
6805-41-0
RhoA protein, mouse
EC 3.6.5.2
rhoA GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113554Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.